Literature DB >> 17242301

Increased susceptibility to atrial tachyarrhythmia in spontaneously hypertensive rat hearts.

Stéphanie C M Choisy1, Lesley A Arberry, Jules C Hancox, Andrew F James.   

Abstract

Although hypertension is the most prevalent risk factor for atrial fibrillation, there is currently no information available from animal models of hypertension regarding the development of atrial remodeling or increased susceptibility to atrial tachyarrhythmia. Therefore, we examined the susceptibility to atrial tachyarrhythmia and the development of atrial remodeling in excised perfused hearts from male spontaneously hypertensive rats in comparison with age-matched male Wistar-Kyoto normotensive controls at age 3 and 11 months, corresponding with early hypertension and pre-heart failure stages, respectively. The incidence and duration of left atrial tachyarrhythmia induced by burst pacing was greater in hearts from 11-month-old hypertensive animals than either in age-matched controls or in 3-month-old hypertensive rats, although there was no difference between hypertensive and normotensive hearts at 3 months. Thus, hypertension was associated with the development of an arrhythmic substrate. Atrial effective refractory period and the duration of monophasic action potentials recorded from the left atrium were not altered with either hypertension or age, although there were changes in the whole-cell Ca2+ current density of isolated left atrial myocytes. On the other hand, Masson's trichrome staining of wax-embedded sections of left atrium revealed markedly greater interstitial fibrosis in 11-month-old hypertensive rats compared with controls. These data constitute the first experimental evidence that hypertension is associated with the development of a substrate for atrial tachyarrhythmia involving left atrial fibrosis without changes in the atrial effective refractory period and demonstrate that the spontaneously hypertensive rat represents a suitable model for investigating hypertension-associated atrial remodeling.

Entities:  

Mesh:

Year:  2007        PMID: 17242301     DOI: 10.1161/01.HYP.0000257123.95372.ab

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  29 in total

1.  Remodeling of atrial ATP-sensitive K⁺ channels in a model of salt-induced elevated blood pressure.

Authors:  Joshua M Lader; Carolina Vasquez; Li Bao; Karen Maass; Jiaxiang Qu; Eirini Kefalogianni; Glenn I Fishman; William A Coetzee; Gregory E Morley
Journal:  Am J Physiol Heart Circ Physiol       Date:  2011-07-01       Impact factor: 4.733

2.  An implantable system for long-term assessment of atrial fibrillation substrate in unanesthetized rats exposed to underlying pathological conditions.

Authors:  Hadar Klapper-Goldstein; Michael Murninkas; Roni Gillis; Wesam Mulla; Eran Levanon; Sigal Elyagon; Ronen Schuster; Dor Danan; Hagit Cohen; Yoram Etzion
Journal:  Sci Rep       Date:  2020-01-17       Impact factor: 4.379

3.  Relaxin suppresses atrial fibrillation by reversing fibrosis and myocyte hypertrophy and increasing conduction velocity and sodium current in spontaneously hypertensive rat hearts.

Authors:  Ashish Parikh; Divyang Patel; Charles F McTiernan; Wenyu Xiang; Jamie Haney; Lei Yang; Bo Lin; Aaron D Kaplan; Glenna C L Bett; Randall L Rasmusson; Sanjeev G Shroff; David Schwartzman; Guy Salama
Journal:  Circ Res       Date:  2013-06-07       Impact factor: 17.367

Review 4.  Atrial fibrillation: mechanisms, therapeutics, and future directions.

Authors:  Jason Pellman; Farah Sheikh
Journal:  Compr Physiol       Date:  2015-04       Impact factor: 9.090

Review 5.  Mechanisms of termination and prevention of atrial fibrillation by drug therapy.

Authors:  A J Workman; G L Smith; A C Rankin
Journal:  Pharmacol Ther       Date:  2011-02-18       Impact factor: 12.310

Review 6.  More types than one: multiple muscarinic receptor coupled K+ currents undergo remodelling in an experimental model of atrial fibrillation.

Authors:  A F James; J C Hancox
Journal:  Br J Pharmacol       Date:  2007-09-10       Impact factor: 8.739

Review 7.  Aldosterone mediates cardiac fibrosis in the setting of hypertension.

Authors:  Feriel Azibani; Loubina Fazal; Christos Chatziantoniou; Jane-Lise Samuel; Claude Delcayre
Journal:  Curr Hypertens Rep       Date:  2013-08       Impact factor: 5.369

8.  P-wave duration in lead aVR and the risk of atrial fibrillation in hypertension.

Authors:  Pietro Francia; Agnese Ricotta; Cristina Balla; Carmen Adduci; Lorenzo Semprini; Alessandra Frattari; Anna Modestino; Federico Mercanti; Isabella Sensini; Massimo Caprinozzi; Giuliano Tocci; Massimo Volpe
Journal:  Ann Noninvasive Electrocardiol       Date:  2014-09-09       Impact factor: 1.468

9.  Clinical outcomes of atrial fibrillation with hyperthyroidism.

Authors:  Muhammad Zubair Khan; Ashwani Gupta; Jordesha Hodge; Kirtenkumar Patel; Krunalkumar Patel; Muhammad Samsoor Zarak; Sona Franklin; Harsh Patel; Shruti Jesani; Sejal Savani; Vraj Shah; Vincent M Figueredo; Arvind R Cavale; Steven Kutalek
Journal:  J Arrhythm       Date:  2021-07-07

10.  Reduced density and altered regulation of rat atrial L-type Ca2+ current in heart failure.

Authors:  Richard C Bond; Simon M Bryant; Judy J Watson; Jules C Hancox; Clive H Orchard; Andrew F James
Journal:  Am J Physiol Heart Circ Physiol       Date:  2016-12-06       Impact factor: 4.733

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.